Compare DDI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDI | ARMP |
|---|---|---|
| Founded | 2008 | N/A |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.7M | 383.7M |
| IPO Year | 2020 | 1996 |
| Metric | DDI | ARMP |
|---|---|---|
| Price | $10.97 | $9.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $19.00 | $15.00 |
| AVG Volume (30 Days) | ★ 159.8K | 67.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.09 | $1.17 |
| 52 Week High | $11.25 | $14.98 |
| Indicator | DDI | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 79.83 | 41.78 |
| Support Level | $8.46 | $5.14 |
| Resistance Level | $11.08 | $12.11 |
| Average True Range (ATR) | 0.27 | 1.61 |
| MACD | 0.19 | -0.44 |
| Stochastic Oscillator | 95.69 | 6.03 |
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States, while it also has its presence in Canada, Germany, United Kingdom, and International-Other. The games offered by the company are: Doubledown Casion, Doubledown Fortknox, and Doubledown Classic Slots.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.